RIZMOIC

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug RIZMOIC contains one active pharmaceutical ingredient (API):

1 Naldemedine UNII V1N8F1RVVO - NALDEMEDINE TOSYLATE

Naldemedine is an antagonist of opioid binding at the mu-, delta-, and kappa-opioid receptors. Naldemedine functions as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids without reversing the central nervous system (CNS)-mediated opioid effects. Read about Naldemedine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RIZMOIC Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A06AH05		A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AH Peripheral opioid receptor antagonists
Discover more medicines within A06AH05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1789588, 1789599, 1789601, 1808568, 1808579, 1808580, 1808591
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1181291002
Country: FR	Base de données publique des médicaments	Identifier(s): 66266368
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 377654
Country: IT	Agenzia del Farmaco	Identifier(s): 047626015, 047626027, 047626039, 047626041, 047626054, 047626066
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1087063, 1087064, 1087065, 1088429, 1088430, 1088431
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100417040